Literature DB >> 17984314

Clinical stem-cell sources contain CD8+CD3+ T-cell receptor-negative cells that facilitate bone marrow repopulation with hematopoietic stem cells.

Stephanie Bridenbaugh1, Linda Kenins, Emilie Bouliong-Pillai, Christian P Kalberer, Elena Shklovskaya, Alois Gratwohl, Aleksandra Wodnar-Filipowicz.   

Abstract

Clinical observations in patients undergoing bone marrow transplantation implicate the involvement of CD8(+) cells in promoting the stem-cell engraftment process. These findings are supported by mouse transplant studies, which attributed the engraftment-facilitating function to subpopulations of murine CD8(+) cells, but the analogous cells in humans have not been identified. Here, we report that clinical stem-cell grafts contain a population of CD8alpha(+)CD3epsilon(+) T-cell receptor- negative cells with an engraftment facilitating function, named candidate facilitating cells (cFCs). Purified cFC augmented human hematopoiesis in NOD/SCID mice receiving suboptimal doses of human CD34(+) cells. In vitro, cFCs cocultured with CD34(+) cells increased hematopoietic colony formation, suggesting a direct effect on clonogenic precursors. These results provide evidence for the existence of rare human CD8(+)CD3(+)TCR(-) cells with engraftment facilitating properties, the adoptive transfer of which could improve the therapeutic outcome of stem-cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17984314     DOI: 10.1182/blood-2007-02-076000

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Ex vivo expanded hematopoietic stem cells overcome the MHC barrier in allogeneic transplantation.

Authors:  Junke Zheng; Masato Umikawa; Shichuan Zhang; HoangDinh Huynh; Robert Silvany; Benjamin P C Chen; Lieping Chen; Cheng Cheng Zhang
Journal:  Cell Stem Cell       Date:  2011-08-05       Impact factor: 24.633

2.  Schwann cells secrete extracellular vesicles to promote and maintain the proliferation and multipotency of hDPCs.

Authors:  Ziyue Li; Yan Liang; Kuangwu Pan; Hui Li; Mei Yu; Weihua Guo; Guoqing Chen; Weidong Tian
Journal:  Cell Prolif       Date:  2017-08       Impact factor: 6.831

3.  Human acute myeloid leukemia CD34+CD38- stem cells are susceptible to allorecognition and lysis by single KIR-expressing natural killer cells.

Authors:  Ulrich Langenkamp; Uwe Siegler; Simon Jörger; Stefan Diermayr; Alois Gratwohl; Christian P Kalberer; Aleksandra Wodnar-Filipowicz
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

Review 4.  Evolving approaches of hematopoietic stem cell-based therapies to induce tolerance to organ transplants: the long road to tolerance.

Authors:  J Leventhal; J Miller; M Abecassis; D J Tollerud; S T Ildstad
Journal:  Clin Pharmacol Ther       Date:  2012-10-10       Impact factor: 6.875

5.  Characterization of Human CD8(+)TCR(-) Facilitating Cells In Vitro and In Vivo in a NOD/SCID/IL2rγ(null) Mouse Model.

Authors:  Y Huang; M J Elliott; E S Yolcu; T O Miller; J Ratajczak; L D Bozulic; Y Wen; H Xu; M Z Ratajczak; S T Ildstad
Journal:  Am J Transplant       Date:  2015-11-09       Impact factor: 8.086

6.  Differential CXCR4 expression on hematopoietic progenitor cells versus stem cells directs homing and engraftment.

Authors:  Sydney Felker; Archana Shrestha; Jeff Bailey; Devin M Pillis; Dylan Siniard; Punam Malik
Journal:  JCI Insight       Date:  2022-05-09

7.  Plasmacytoid precursor dendritic cells from NOD mice exhibit impaired function: are they a component of diabetes pathogenesis?

Authors:  Yiming Huang; Isabelle J Fugier-Vivier; Thomas Miller; Mary J Elliott; Hong Xu; Larry D Bozulic; Paula M Chilton; Suzanne T Ildstad
Journal:  Diabetes       Date:  2008-06-20       Impact factor: 9.461

Review 8.  Impact of T cells on hematopoietic stem and progenitor cell function: Good guys or bad guys?

Authors:  Sulima Geerman; Martijn A Nolte
Journal:  World J Stem Cells       Date:  2017-02-26       Impact factor: 5.326

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.